GEA Engineering for a better world.

Q3 2026 RESULTS

Stefan Klebert, CEO
Alexander Kocherscheidt, CFO

Düsseldorf, November 9, 2026

Disclaimer

This presentation contains forward-looking statements. Forward-looking statements may include, in particular, statements about future events, future financial performance, plans, strategies, expectations, prospects, competitive environment, regulation and supply and demand. Statements with respect to the future are characterized by the use of words such as "expect", "intend", "plan", "anticipate", "believe", "estimate" and similar terms. Forward-looking statements are based on our current assumptions and forecasts. These statements naturally entail risks and uncertainties, which may cause the actual results of operations, financial position or performance to diverge materially from the estimates given here. Factors that could cause such a divergence include, inter alia, changes in the economic and business environment, fluctuations in exchange rates and interest rates, launches of competing products, poor acceptance of new products or services, and changes in business strategy. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. We undertake no obligation to update or revise any forward-looking statements.

Due to rounding, the sum of percentages of order intake and sales by region as well as by customer industry may vary from 100%.

HIGHLIGHTS Q3 2026

Stefan Klebert, CEO



Executive Summary Q3 2026

Significant order intake growth, strong sales development & further EBITDA[1] margin expansion

€m	Q3 26	Q3 25	Δ reported	Δ organic	
Order intake	1,651	1,372	20.3%	19.5%	Large order (>€15m) volume of €295m vs. large order volume of €64m in Q3 25; strong growth in base orders
Sales	1,461	1,366	7.0%	6.2%	Strong organic service sales and solid organic new machine sales growth
EBITDA[1] **EBITDA[1] margin**	260.9 17.9%	231.7 17.0%	12.6% 0.9%p		EBITDA[1] expansion driven by higher gross profit[1]
EBIT[1] **EBIT[1] margin**	202.1 13.8%	179.7 13.2%	12.5% 0.7%p		
ROCE[1,2]	37.8%	35.4%	2.4%p		New record level
Net liquidity[3]	115.2	-36.3	151.5		Increase in net liquidity despite share buyback program

[1] Before restructuring expenses I [2] Capital Employed as average of the last 4 quarters I [3] Net liquidity at the end of Q3 2026 including lease liabilities of €275m (Q3 2025: €217m)

Share buyback of €500m until 2027

1st tranche of €250m to end in Q1 2027

€58.3m

Executed[2]

€500m

Total program



As of September 30, 2026[1]

Shares repurchased

893.3k

0.55% of outstanding shares[3]

Average purchase price

€65.32

per share

[1] As of November 6th €91.6m executed, so 18.3% of the total has been executed I [2] Thereof €54m already reflected in cash flow statement as of 30.09.2026 I [3] Shares outstanding per 30.09.2026: 162.8m; as of November 6th, GEA bought back 0.85% of outstanding shares

Continuous tableting is increasingly gaining traction

From proven commercial use to broader adoption

2019–2023

R&D SYSTEMS

Multiple R&D systems supplied for new drug development

2024–2025

FOLLOW-ON ORDERS

Multiple orders secured for commercial launch

Q3 2026

COMMERCIAL SCALE

Several lines sold for commercial production

MISSION 30

GROWTH OUTLOOK

Expected sales CAGR of 15–20% until 2030



From days to hours: Continuous tableting is a game changer

TRADITIONAL BATCH
Usually 8 steps



Sequential operations • intermediate storage • testing and release at the end • separate rooms • long production time

CONTINUOUS
One contained flow

Powder in → integrated powder-to-tablet process → tablet out

Real-time deviation detection, in-line quality control • reduced footprint

---

SAVINGS[1]

PRODUCTION TIME	COST PER TABLET[2]	TIME TO MARKET	FOOTPRINT
>90%	up to 40%	> 60%	up to 30%

[1] Based on customer feedback I [2] Based on lower conversion cost, higher yield and fewer rejects; includes 30% less waste, shorter manufacturing and testing cycle time and shorter time from testing to release.


BUSINESS & FINANCIAL REVIEW Q3 2026

Alexander Kocherscheidt, CFO



GEA Group

Q3 26: Strong top-line growth & another meaningful EBITDA[1] margin increase



Organic order intake ↑ 19.5% YoY
- Organic order intake growth in all divisions
- Growth in almost all customer industries, especially Dairy Processing, Beverage and Pharma
- €14m positive FX translation effect (+1.0%)


Organic sales ↑ 6.2% YoY
- Organic new machine sales up by 4.6% YoY
- Organic service sales growth of 8.6% YoY
- Service sales share up by 0.8%p to 40.9%
- €13m positive FX translation effect (+0.9%)

EBITDA[1] margin ↑ to 17.9% (Q3 25: 17.0%)
- Gross profit[1] rose due to volume
- Operating costs[2] increased YoY

[1] Before restructuring expenses I [2] Operating costs defined as difference between gross profit[1] and EBITDA[1]

Division Pure Flow Processing (PFP)

Q3 26: Strong improvement in all KPIs



Organic order intake ↑ 8.3% YoY
- Strong development in orders below €5m
- Growth has been broad-based; biggest contribution were coming from customer industries Dairy Processing, Food & Marine
- €6m positive FX translation effect (+1.2%)


Organic sales ↑ 8.7% YoY
- Organic new machine sales up by 9.9% YoY
- Organic service sales growth of 7.3% YoY
- Service sales share down by 0.6%p to 46.4%

EBITDA¹ margin ↑ to 26.9% (Q3 25: 26.4%)
- Gross profit¹ rose due to volume
- Operating costs² increased slightly YoY

¹ Before restructuring expenses I ² Operating costs defined as difference between gross profit¹ and EBITDA¹

Division Nutrition Plant Engineering (NPE)

Q3 26: Very strong order intake growth, further pick-up in sales & profitability



Organic order intake ↑ 37.6% YoY

- Large order (>€15m) volume of €192m in Dairy Processing and Beverage vs. large order volume of €48m in Q3 2025
- Growth mainly driven by customer industries Beverage and Dairy Processing
- €5m positive FX translation effect (+1.1%)

Organic sales ↑ 5.8% YoY

- Organic new machine sales up by 2.4% YoY
- Organic service sales growth of 13.6% YoY
- Service sales share up by 2.3%p to 33.0%


EBITDA[1] margin ↑ to 11.8% (Q3 25: 11.4%)

- Gross profit[1] increased due to volume and higher service share
- Operating costs[2] increased YoY

[1] Before restructuring expenses I [2] Operating costs defined as difference between gross profit[1] and EBITDA[1]

Division Pharma & Food Applications (PFA)

Q3 26: Large order volume >€100m & substantial YoY EBITDA[1] margin improvement



Organic order intake ↑ 20.2% YoY
- Large order (>€15m) volume of €103m in Pharma vs. no large order last year
- €2m positive FX translation effect (+0.6%)


Organic sales ↑ 3.9% YoY
- Organic new machine sales up by 5.2% YoY
- Organic service sales growth of 1.6% YoY
- Service sales share down by 1.4%p to 35.6%

EBITDA[1] margin ↑ to 16.1% (Q3 25: 13.3%)
- Gross profit[1] rose YoY due to volume and significantly higher gross margin
- Operating costs[2] increased YoY

[1] Before restructuring expenses I [2] Operating costs defined as difference between gross profit[1] and EBITDA[1]

Division Farm Technologies (FT)

Q3 26: Solid organic order intake development & strong organic sales growth



Organic order intake ↑ 4.1% YoY
- Growth driven by strong demand for service in all regions
- €2m positive FX translation effect (+0.9%)

Organic sales ↑ 9.9% YoY
- Organic new machine sales up by 7.4% YoY
- Organic service sales growth of 12.6% YoY
- Service sales share up by 1.2%p to 49.6%


EBITDA[1] margin ↓ to 16.4% (Q3 25: 18.0%)
- Gross profit[1] stable YoY
- Operating costs[2] increased slightly YoY

[1] Before restructuring expenses I [2] Operating costs defined as difference between gross profit[1] and EBITDA[1]


Strong EBITDA[1] performance in 9M and Q3 2026

Positive contribution by all divisions in both time periods

9M 26 EBITDA[1] growth contribution by divisions in €m



Q3 26 EBITDA[1] growth contribution by divisions in €m




[1] Before restructuring expenses

Net Working Capital performance

NWC/sales ratio comfortably within the guided corridor

- YoY NWC reduction due to a combination of higher contract liabilities (advance payments) and higher trade payables
- NWC ratio with 7.8% within the guided corridor of 7.0 – 9.0%






Good cash generation

FCF

- NWC -€52m: outflow mainly driven by higher trade receivables
- Positive FCF of €135m


Free Cash Flow Q3 26, €m



Net Cash

- Good cash generation
- €54m cash out for share buyback


Net Cash at the end of Q3 26 vs. at the end of Q2 26, €m




[1] Including lease liabilities of €275m at the end of Q3 2026 and €261m at the end of Q2 2026

Strong cash conversion[1] of 61% in L4Q

Free Cash Flow 9M 26, €m



FCF generation during L4Q per Q3 26, €m



[1] Before restructuring expenses; FCF conversion ratio defined as %age of EBITDA[1] converted into FCF[1]

OUTLOOK FY 2026

Stefan Klebert, CEO



Guidance for FY 2026 confirmed

Organic sales growth
(currency and portfolio adjusted)
% YoY

6.0-8.0

(FY 2025: 3.7%)

EBITDA margin
(Before restructuring expenses)
%

17.0-17.4

(FY 2025: 16.5%)

ROCE[1]
(Before restructuring expenses)
%

36.0-40.0

(FY 2025: 36.2%)

For divisional guidance, please refer to slide 32 in the appendix I [1] Capital Employed as average of the last 4 quarters.

Roadmap for remainder of 2026 and 2027




APPENDIX

GEA – Q3 2026 figures


[in €m]	Q3 25	Q3 26	Δ YoY	L4Q Q3 25	L4Q Q3 26	Δ YoY
Order Intake	1.372,4	**1.650,7**	20,3%	5.694,4	**6.427,3**	12,9%
Organic[1]			19,5%			14,9%
Sales	1.365,9	**1.461,2**	7,0%	5.443,9	**5.736,1**	5,4%
Organic[1]			6,2%			7,4%
Order Backlog	3.102,3	**3.722,2**	20,0%	3.102,3	**3.722,2**	20,0%
EBITDA[2]	231,7	**260,9**	12,6%	885,8	**978,0**	10,4%
EBITDA Margin[2]	17,0%	**17,9%**	89 bps	16,3%	**17,1%**	78 bps
EBIT[2]	179,7	**202,1**	12,5%	665,8	**740,4**	11,2%
EBIT Margin[2]	13,2%	**13,8%**	67 bps	12,2%	**12,9%**	68 bps
ROCE[3]	35,4%	**37,8%**	239 bps	35,4%	**37,8%**	239 bps

Sales by Customer Industry (L4Q)




Dairy Farming	12% YoY
Dairy Processing	21% YoY
Food	1% YoY
New Food	44% YoY
Beverage	-8% YoY
Pharma	17% YoY
Chemical	-23% YoY
Other	5% YoY
GEA	5% YoY

Order Intake and Sales (L4Q in €m)



Order Intake Development by Size (in €m)




[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses; [3] Capital Employed as average of the last 4 quarters (L4Q)

Pure Flow Processing – Q3 2026 figures

[in €m]	Q3 25	Q3 26	Δ YoY	L4Q Q3 25	L4Q Q3 26	Δ YoY
Order Intake	500,7	**548,1**	9,5%	2.023,8	**2.155,9**	6,5%
Organic[1]			8,3%			8,5%
Sales	481,5	**529,3**	9,9%	1.945,2	**2.067,7**	6,3%
Organic[1]			8,7%			8,2%
Order Backlog	767,5	**831,2**	8,3%	767,5	**831,2**	8,3%
EBITDA[2]	127,1	**142,4**	12,0%	517,8	**554,0**	7,0%
EBITDA Margin[2]	26,4%	**26,9%**	50 bps	26,6%	**26,8%**	17 bps
EBIT[2]	110,8	**124,6**	12,5%	452,1	**483,2**	6,9%
EBIT Margin[2]	23,0%	**23,5%**	54 bps	23,2%	**23,4%**	13 bps
ROCE[3]	40,1%	**41,1%**	96 bps	40,1%	**41,1%**	96 bps

Sales by Customer Industry (L4Q)




Dairy Farming	n.a
Dairy Processing	21% YoY
Food	-6% YoY
New Food	-23% YoY
Beverage	9% YoY
Pharma	10% YoY
Chemical	-28% YoY
Other	7% YoY
PFP	6% YoY

Order Intake and Sales (L4Q in €m)



Order Intake Development by Size (in €m)




[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses I [3] ROCE, as one of the relevant performance indicators, is considered as „ROCE 3rd Party" (excluding interdivisional effects in the capital employed) at the divisional level. Capital Employed as average of the last 4 quarters (L4Q)

Nutrition Plant Engineering – Q3 2026 figures

[in €m]	Q3 25	Q3 26	Δ YoY	L4Q Q3 25	L4Q Q3 26	Δ YoY
Order Intake	453,9	**629,2**	38,6%	1.999,4	**2.485,4**	24,3%
Organic[1]			37,6%			26,1%
Sales	488,9	**520,9**	6,5%	1.940,4	**1.997,2**	2,9%
Organic[1]			5,8%			4,5%
Order Backlog	1.501,4	**1.950,2**	29,9%	1.501,4	**1.950,2**	29,9%
EBITDA[2]	55,7	**61,3**	10,0%	208,3	**230,1**	10,4%
EBITDA Margin[2]	11,4%	**11,8%**	37 bps	10,7%	**11,5%**	78 bps
EBIT[2]	45,5	**50,5**	10,9%	164,2	**185,7**	13,0%
EBIT Margin[2]	9,3%	**9,7%**	38 bps	8,5%	**9,3%**	83 bps
ROCE[3]	n.a	**n.a**	-	n.a	**n.a**	-

Sales by Customer Industry (L4Q)




Dairy Farming	n.a
Dairy Processing	20% YoY
Food	11% YoY
New Food	48% YoY
Beverage	-14% YoY
Pharma	187% YoY
Chemical	-22% YoY
Other	-1% YoY
NPE	3% YoY

Order Intake and Sales (L4Q in €m)



Order Intake Development by Size (in €m)




[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses I [3] ROCE, as one of the relevant performance indicators, has now been considered as „ROCE 3rd Party" (excluding interdivisional effects in the capital employed) at the divisional level since the beginning of the financial year 2021. Due to negative capital employed, ROCE is not meaningful.

Pharma & Food Applications – Q3 2026 figures

[in €m]	Q3 25	Q3 26	Δ YoY	L4Q Q3 25	L4Q Q3 26	Δ YoY
Order Intake	270,0	**323,2**	19,7%	1.102,3	**1.139,4**	3,4%
Organic[1]			20,2%			5,6%
Sales	252,0	**261,0**	3,6%	1.042,0	**1.080,9**	3,7%
Organic[1]			3,9%			6,8%
Order Backlog	661,8	**714,5**	8,0%	661,8	**714,5**	8,0%
EBITDA[2]	33,4	**41,9**	25,6%	130,7	**161,8**	23,8%
EBITDA Margin[2]	13,3%	**16,1%**	281 bps	12,5%	**15,0%**	242 bps
EBIT[2]	21,9	**30,0**	37,1%	77,3	**107,9**	39,6%
EBIT Margin[2]	8,7%	**11,5%**	281 bps	7,4%	**10,0%**	257 bps
ROCE[3]	16,5%	**23,6%**	713 bps	16,5%	**23,6%**	713 bps

Sales by Customer Industry (L4Q)




Dairy Farming	40% YoY
Dairy Processing	n.a
Food	1% YoY
New Food	78% YoY
Beverage	n.a
Pharma	9% YoY
Chemical	n.a
Other	-63% YoY
PFA	4% YoY

Order Intake and Sales (L4Q in €m)



Order Intake Development by Size (in €m)




[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses I [3] ROCE, as one of the relevant performance indicators, is considered as „ROCE 3rd Party" (excluding interdivisional effects in the capital employed) at the divisional level. Capital Employed as average of the last 4 quarters (L4Q)

Farm Technologies – Q3 2026 figures


[in €m]	Q3 25	Q3 26	Δ YoY	L4Q Q3 25	L4Q Q3 26	Δ YoY
Order Intake	205,1	215,4	5,0%	811,1	922,0	13,7%
Organic[1]			4,1%			15,4%
Sales	200,7	222,7	10,9%	750,6	847,9	13,0%
Organic[1]			9,9%			14,7%
Order Backlog	236,9	312,3	31,8%	236,9	312,3	31,8%
EBITDA[2]	36,1	36,5	1,3%	115,4	129,2	11,9%
EBITDA Margin[2]	18,0%	16,4%	-156 bps	15,4%	15,2%	-14 bps
EBIT[2]	29,3	26,1	-11,0%	86,1	91,1	5,8%
EBIT Margin[2]	14,6%	11,7%	-289 bps	11,5%	10,7%	-73 bps
ROCE[3]	30,9%	32,6%	170 bps	30,9%	32,6%	170 bps

Sales by Customer Industry (L4Q)




Dairy Farming	13% YoY
Dairy Processing	n.a
Food	n.a
New Food	n.a
Beverage	n.a
Pharma	n.a
Chemical	n.a
Other	n.a
FT	13% YoY

Order Intake and Sales (L4Q in €m)




Order Intake Development by Size (in €m)



[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses I [3] ROCE, as one of the relevant performance indicators, is considered as „ROCE 3rd Party" (excluding interdivisional effects in the capital employed) at the divisional level. Capital Employed as average of the last 4 quarters (L4Q)

Good order intake development

Order intake rolling L4Q in €m



Order intake split as of Q3 2026 L4Q:

Top 30 countries account for 87% of order intake

Top DM Countries	Share	Delta LTM %	BtB
United States	18%	↑	1,16
Germany	8%	↑	1,08
United Kingdom	4%	↑	1,14
Spain	4%	↑	1,17
Netherlands	4%	↑	1,03
Ireland	3%	↑	1,79
France	3%	↑	1,12
Sweden	3%	↑	2,65
Italy	2%	→	1,09
Canada	2%	↓	0,87
Japan	2%	↑	1,44
Belgium	1%	↓	0,81
Denmark	1%	↑	1,00
Australia	1%	↗	0,98
New Zealand	1%	↑	0,82

Top EM Countries	Share	Delta LTM %	BtB
China	8%	↑	1,16
India	3%	↑	1,15
Poland	3%	↗	0,99
Algeria	2%	↑	4,47
Brazil	2%	↑	1,05
Turkey	2%	↑	1,33
Mexico	2%	↓	1,05
Argentina	1%	↗	1,05
Indonesia	1%	↓	0,95
South Africa	1%	↑	1,12
Thailand	1%	↑	1,22
Saudi Arabia	1%	↓	0,82
Vietnam	1%	↓	0,61
Russian Federation	1%	↓	1,07
Hungary	1%	↑	1,81

More than 5%	↑
Between 1% and 5%	↗
Between -1% and 1%	→
Between -5% and -1%	↘
Less than -5%	↓

Classification based on World Economic Outlook, October 2025

FX development

Currency	% total Sep YTD *	FX rates Sep YTD (average)	Δ FX YoY Sep 2026 vs Sep 2025
EUR	43%	-	-
USD	19%	1,16	4%
CNY	6%	7,92	-2%
DKK	5%	7,47	0%
GBP	4%	0,86	1%
PLN	3%	4,27	1%
CAD	2%	1,61	3%
INR	2%	109,07	13%
BRL	2%	5,98	-5%
NZD	2%	1,98	4%
AUD	1%	1,65	-5%

*Share of functional (i.e. local P&Ls) currencies in the translation mix of the group;
all figures on a YTD basis

Strong financial position and solid financial flexibility

Maturity structure cash credit lines (€m)

Maturity/Year	Limit	Utilized	Comments
2028	650	0	Committed syndicated liquidity back-up credit facility of Headquarter. Linked to ESG indicators.
Until further notice	30	0	Evergreens, committed bilateral credit lines of Headquarter with core banks.
Until further notice	0.3	0.3	Bilateral lines of subsidiaries.
Total	**680.3**	**0.3**	

Agency	Last Update	Rating		Outlook	
		Current	Prior	Current	Prior
S&P	September 2026	BBB+	na	stable	na
Moody‘s	June 2026	Baa1	Baa1	stable	stable

Finance KPIs

€m	End of Q3 26	End of Q3 25	Δ
Cash and cash equivalents	390	288	↑
Current securities	1	-	↑
- Bank liabilities (incl. accrued interest)	0	107	↓
= Net liquidity excl. lease liabilities	390	181	↑
- Lease liabilities	275	217	↑
= Net liquidity / net debt (incl. lease liabilities)	115	(36)	↑

Additional financial information for FY 2026

Depreciation & Amortization (incl. PPA, IFRS 16)[1]

around
€230m

thereof impact from PPA

around
€10m

Financial result

around
-€30m

Tax rate

between
28-30%[2]

Capex

around
€240m

R&D (as % of sales)

around
3%

[1] Before restructuring expenses I [2] Estimation does not include a potential additional change of valuation allowances on deferred tax assets on tax loss carryforwards based on new business prognosis by the end of the fiscal year.

Divisional guidance FY 2026 confirmed

Revenue development (organic[1])	Forecast for 2026	2025
Pure Flow Processing	+4.5% to +7.0%	€1,953m
Nutrition Plant Engineering	+7.0% to +9.0%	€1,955m
Pharma & Food Applications	+6.0% to +8.0%	€1,058m
Farm Technologies	+8.0% to +10.0%	€763m
Consolidation	-	-€234m

EBITDA margin before restructuring	Forecast for 2026	2025
Pure Flow Processing	27.0% to 28.5%	26.7%
Nutrition Plant Engineering	11.5% to 13.0%	11.4%
Pharma & Food Applications	14.0% to 15.5%	13.3%
Farm Technologies	15.0% to 16.5%	14.8%
Others / Consolidation[4]	-1.5%	-1.7%

ROCE[2] (3rd Party)	Forecast for 2026	2025
Pure Flow Processing	37.0% to 43.0%	40.5%
Nutrition Plant Engineering[3]	-	-
Pharma & Food Applications	24.0% to 28.0%	19.3%
Farm Technologies	31.0% to 36.0%	28.9%

[1] Adjusted for portfolio and currency translation effects I [2] Capital Employed as average of the last 4 quarters I [3] Due to negative capital employed ROCE in 2025 and 2026 is not meaningful I [4] In percentage of total revenue

Historical timeline (1/4)

Order Intake €m	Q1 24	Q2 24	Q3 24	Q4 24	FY 24	Q1 25	Q2 25	Q3 25	Q4 25	FY 25	Q1 26	Q2 26	Q3 26
PFP	504	470	455	517	1.946	507	499	501	514	2.020	551	544	548
NPE	457	466	509	662	2.094	482	402	454	835	2.172	460	561	629
PFA	259	254	238	302	1.052	268	263	270	308	1.109	274	234	323
FT	199	158	161	185	703	214	207	205	241	868	236	230	215
Cons./ Other	(53)	(59)	(63)	(68)	(243)	(56)	(61)	(57)	(70)	(245)	(66)	(74)	(65)
GEA	1.365	1.289	1.301	1.598	5.553	1.415	1.309	1.372	1.828	5.924	1.454	1.495	1.651
Order Intake Group < 1 €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	424	418	418	453	1.713	446	435	408	438	1.727	475	486	464
NPE	216	232	197	237	882	208	225	208	224	865	220	229	212
PFA	157	155	149	164	625	163	143	144	150	600	159	152	149
FT	183	155	156	182	676	196	192	188	193	769	218	216	190
GEA	927	900	866	979	3.673	964	938	894	948	3.744	1.019	1.019	960
Order Intake Group >= 1 €m < 5 €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	62	52	37	58	209	61	53	60	62	235	69	57	84
NPE	128	126	141	120	514	108	117	99	122	445	108	175	103
PFA	69	69	68	67	274	74	67	80	109	330	81	51	58
FT	15	4	5	3	27	18	15	17	9	59	18	13	17
GEA	274	250	243	238	1.005	254	248	252	293	1.047	265	287	253
Order Intake Group >= 5 €m < 15 €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	18	-	-	6	24	-	11	17	14	41	6	-	-
NPE	83	26	112	113	334	83	59	99	144	385	58	123	122
PFA	13	15	20	33	81	32	53	46	20	151	33	31	13
FT	-	-	-	-	-	-	-	-	-	-	-	-	8
GEA	113	41	133	151	438	114	123	162	173	572	97	155	144
Order Intake Group >= 15 €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	-	-	-	-	-	-	-	16	-	16	-	-	-
NPE	31	83	59	192	364	83	-	48	346	477	73	34	192
PFA	20	15	-	38	73	-	-	-	28	28	-	-	103
FT	-	-	-	-	-	-	-	-	40	40	-	-	-
GEA	51	98	59	230	437	83	-	64	414	561	73	34	295
Organic Order Intake Growth1	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	n.a	n.a	n.a	n.a	n.a	0,0%	8,5%	13,3%	3,0%	6,0%	13,0%	9,8%	8,3%
NPE	n.a	n.a	n.a	n.a	n.a	5,3%	-11,3%	-8,8%	29,3%	5,8%	-2,1%	41,7%	37,6%
PFA	3,1%	-11,5%	0,6%	19,7%	2,5%	4,2%	10,0%	16,0%	5,4%	8,6%	5,9%	-9,6%	20,2%
FT	-14,7%	-12,8%	1,1%	9,4%	-5,4%	7,2%	34,3%	31,2%	34,5%	26,0%	13,7%	11,4%	4,1%
GEA	-9,7%	-3,5%	6,6%	29,3%	4,6%	3,4%	5,0%	8,4%	17,9%	9,1%	6,4%	15,4%	19,5%

[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects

Historical timeline (2/4)

Order Backlog €m	Q1 24	Q2 24	Q3 24	Q4 24	FY 24	Q1 25	Q2 25	Q3 25	Q4 25	FY 25	Q1 26	Q2 26	Q3 26
PFP	786	788	744	747	747	760	757	767	743	743	816	815	831
NPE	1.576	1.544	1.518	1.625	1.625	1.650	1.551	1.501	1.725	1.725	1.783	1.844	1.950
PFA	648	659	631	654	654	669	657	662	677	677	686	652	715
FT	289	237	189	170	170	218	235	237	265	265	300	321	312
Cons./ Other	(58)	(64)	(68)	(68)	(68)	(59)	(69)	(65)	(72)	(72)	(84)	(92)	(86)
GEA	3.241	3.164	3.014	3.127	3.127	3.239	3.131	3.102	3.339	3.339	3.501	3.540	3.722
Sales €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	434	463	486	529	1.912	466	469	482	537	1.953	475	527	529
NPE	439	483	473	568	1.962	433	450	489	583	1.955	399	494	521
PFA	238	240	253	277	1.007	251	262	252	293	1.058	249	278	261
FT	187	190	195	201	773	167	182	201	214	763	202	210	223
Cons./ Other	(57)	(52)	(57)	(67)	(233)	(58)	(52)	(57)	(66)	(234)	(52)	(66)	(73)
GEA	1.241	1.323	1.350	1.508	5.422	1.258	1.312	1.366	1.559	5.495	1.273	1.442	1.461
Organic Sales Growth1	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	n.a	n.a	n.a	n.a	n.a	6,5%	3,7%	2,0%	5,2%	4,3%	6,3%	12,9%	8,7%
NPE	n.a	n.a	n.a	n.a	n.a	-1,7%	-4,9%	6,1%	5,8%	1,6%	-4,8%	10,6%	5,8%
PFA	-2,6%	-3,8%	3,4%	-5,0%	-2,2%	5,4%	12,2%	4,1%	10,7%	8,2%	3,9%	8,5%	3,9%
FT	10,4%	1,4%	-4,0%	7,8%	3,7%	-11,4%	-1,6%	6,0%	9,7%	0,9%	26,0%	15,4%	9,9%
GEA	2,7%	1,6%	1,4%	8,7%	3,7%	0,9%	1,5%	4,5%	7,2%	3,7%	5,3%	11,0%	6,2%
Book-to-bill ratio	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	1,16	1,01	0,94	0,98	1,02	1,09	1,06	1,04	0,96	1,03	1,16	1,03	1,04
NPE	1,04	0,97	1,08	1,16	1,07	1,11	0,89	0,93	1,43	1,11	1,15	1,14	1,21
PFA	1,09	1,06	0,94	1,09	1,04	1,07	1,00	1,07	1,05	1,05	1,10	0,84	1,24
FT	1,06	0,83	0,83	0,92	0,91	1,29	1,14	1,02	1,13	1,14	1,17	1,10	0,97
GEA	1,10	0,97	0,96	1,06	1,02	1,12	1,00	1,00	1,17	1,08	1,14	1,04	1,13
EBITDA before restructuring €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	109	119	123	137	487	122	132	127	141	522	126	145	142
NPE	31	47	57	67	202	40	45	56	81	222	32	56	61
PFA	23	24	26	31	103	31	35	33	41	141	33	45	42
FT	27	28	32	32	119	21	26	36	29	113	34	30	37
Cons./ Other	(9)	(16)	(19)	(28)	(73)	(17)	(21)	(21)	(33)	(91)	(19)	(25)	(21)
GEA	181	201	217	239	837	198	217	232	261	907	206	251	261
EBITDA before restructuring margin	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	25,1%	25,6%	25,2%	25,9%	25,5%	26,3%	28,0%	26,4%	26,3%	26,7%	26,5%	27,5%	26,9%
NPE	7,1%	9,6%	12,0%	11,8%	10,3%	9,3%	10,0%	11,4%	14,0%	11,4%	8,0%	11,3%	11,8%
PFA	9,5%	9,8%	10,1%	11,3%	10,2%	12,5%	13,2%	13,3%	14,1%	13,3%	13,4%	16,2%	16,1%
FT	14,5%	14,9%	16,2%	15,8%	15,3%	12,8%	14,4%	18,0%	13,7%	14,8%	16,7%	14,2%	16,4%
GEA	14,5%	15,2%	16,1%	15,9%	15,4%	15,8%	16,5%	17,0%	16,7%	16,5%	16,2%	17,4%	17,9%

[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects

Historical timeline (3/4)

Depreciation & amortization2 €m	Q1 24	Q2 24	Q3 24	Q4 24	FY 24	Q1 25	Q2 25	Q3 25	Q4 25	FY 25	Q1 26	Q2 26	Q3 26
PFP	(14)	(14)	(15)	(16)	(60)	(15)	(17)	(16)	(18)	(66)	(16)	(17)	(17)
NPE	(10)	(10)	(10)	(11)	(40)	(10)	(10)	(10)	(13)	(42)	(10)	(10)	(10)
PFA	(8)	(9)	(9)	(17)	(44)	(9)	(9)	(9)	(16)	(43)	(9)	(9)	(9)
FT	(7)	(6)	(6)	(8)	(26)	(9)	(8)	(7)	(14)	(37)	(7)	(7)	(10)
Cons./ Other	(6)	(7)	(6)	(10)	(29)	(5)	(7)	(7)	(9)	(28)	(7)	(7)	(8)
GEA	(45)	(47)	(46)	(62)	(199)	(47)	(51)	(49)	(69)	(216)	(50)	(51)	(55)
PPA Depreciation & amortization2 €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	(0)	(0)	(0)	(0)	(1)	(0)	(0)	(0)	(0)	(1)	(0)	(0)	(0)
NPE	(0)	(0)	(0)	(2)	(3)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
PFA	(2)	(2)	(2)	(2)	(9)	(2)	(2)	(2)	(2)	(9)	(3)	(2)	(3)
FT	(0)	(0)	(0)	(0)	(0)	2	(0)	0	0	2	(0)	(0)	(0)
Cons./ Other	-	-	-	1	1	-	-	-	0	0	-	-	-
GEA	(3)	(3)	(3)	(4)	(12)	(1)	(3)	(3)	(2)	(10)	(4)	(3)	(4)
EBIT before restructuring €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	95	104	107	120	425	107	115	111	123	455	109	127	125
NPE	21	37	47	54	159	30	35	46	68	179	22	45	50
PFA	12	12	15	12	50	20	23	22	23	88	21	34	30
FT	21	22	25	24	92	14	19	29	16	78	26	23	26
Cons./ Other	(15)	(24)	(25)	(36)	(101)	(22)	(28)	(28)	(41)	(119)	(26)	(32)	(29)
GEA	133	151	168	173	626	150	163	180	189	682	152	197	202
EBIT before restructuring margin	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	21,8%	22,4%	22,0%	22,7%	22,2%	22,9%	24,4%	23,0%	22,9%	23,3%	22,9%	24,1%	23,5%
NPE	4,9%	7,6%	9,9%	9,5%	8,1%	6,9%	7,8%	9,3%	11,7%	9,1%	5,4%	9,1%	9,7%
PFA	4,9%	5,0%	5,7%	4,4%	5,0%	8,1%	8,7%	8,7%	7,9%	8,3%	8,5%	12,1%	11,5%
FT	11,0%	11,6%	12,9%	12,0%	11,9%	8,5%	10,2%	14,6%	7,6%	10,3%	13,0%	10,8%	11,7%
GEA	10,7%	11,4%	12,5%	11,5%	11,5%	11,9%	12,4%	13,2%	12,1%	12,4%	12,0%	13,6%	13,8%
EBITDA €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	107	116	120	134	478	121	130	126	133	511	125	143	139
NPE	30	37	54	60	180	40	44	54	75	212	31	54	61
PFA	20	24	26	23	92	29	34	33	55	152	33	45	29
FT	27	27	31	25	109	19	24	36	25	104	33	25	36
Cons./ Other	(11)	(18)	(21)	(32)	(83)	(19)	(24)	(23)	(55)	(120)	(22)	(26)	(23)
GEA	173	186	209	209	777	191	208	227	233	859	201	241	242

[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses

Historical timeline (4/4)

EBITDA margin	Q1 24	Q2 24	Q3 24	Q4 24	FY 24	Q1 25	Q2 25	Q3 25	Q4 25	FY 25	Q1 26	Q2 26	Q3 26
PFP	24,7%	25,1%	24,7%	25,4%	25,0%	26,0%	27,7%	26,2%	24,8%	26,1%	26,2%	27,1%	26,3%
NPE	6,7%	7,6%	11,4%	10,5%	9,2%	9,2%	9,7%	11,0%	12,8%	10,9%	7,8%	10,9%	11,6%
PFA	8,5%	10,1%	10,1%	8,1%	9,2%	11,7%	12,9%	13,2%	18,7%	14,3%	13,3%	16,0%	11,0%
FT	14,2%	14,2%	15,8%	12,5%	14,2%	11,4%	13,0%	18,0%	11,9%	13,7%	16,5%	12,1%	16,1%
GEA	13,9%	14,0%	15,5%	13,9%	14,3%	15,2%	15,8%	16,6%	15,0%	15,6%	15,7%	16,7%	16,5%
EBIT €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	93	101	104	118	417	106	113	110	115	443	108	125	122
NPE	17	27	44	46	134	30	34	44	62	169	21	43	50
PFA	9	13	12	3	36	18	22	22	37	99	21	33	17
FT	20	21	24	17	83	10	16	29	12	66	26	18	25
Cons./ Other	(17)	(26)	(27)	(42)	(112)	(23)	(31)	(30)	(63)	(147)	(29)	(33)	(31)
GEA	122	136	158	142	558	140	154	174	161	630	147	187	183
EBIT margin	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	21,4%	21,9%	21,5%	22,3%	21,8%	22,7%	24,1%	22,8%	21,3%	22,7%	22,7%	23,7%	23,0%
NPE	3,8%	5,6%	9,3%	8,1%	6,8%	6,9%	7,4%	8,9%	10,6%	8,6%	5,2%	8,7%	9,6%
PFA	4,0%	5,3%	4,6%	1,0%	3,6%	7,3%	8,5%	8,7%	12,5%	9,3%	8,4%	11,9%	6,4%
FT	10,7%	11,0%	12,5%	8,7%	10,7%	5,8%	8,8%	14,3%	5,4%	8,7%	12,9%	8,6%	11,4%
GEA	9,8%	10,3%	11,7%	9,4%	10,3%	11,2%	11,7%	12,8%	10,3%	11,5%	11,5%	12,9%	12,5%
Capital Employed3 (avg. L4Q) €m	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	n.a	n.a	n.a	1.108	1.108	1.112	1.117	1.127	1.124	1.124	1.142	1.163	1.176
NPE	n.a	n.a	n.a	(21)	(21)	(26)	(33)	(35)	(40)	(40)	(39)	(36)	(28)
PFA	460	451	448	453	453	465	467	468	457	457	456	458	457
FT	294	299	302	304	304	297	285	278	271	271	274	279	279
Other	28	22	13	6	6	(6)	15	43	72	72	83	85	77
GEA	1.812	1.824	1.844	1.851	1.851	1.841	1.851	1.882	1.884	1.884	1.916	1.949	1.960
ROCE2,3 (avg. L4Q)	**Q1 24**	**Q2 24**	**Q3 24**	**Q4 24**	**FY 24**	**Q1 25**	**Q2 25**	**Q3 25**	**Q4 25**	**FY 25**	**Q1 26**	**Q2 26**	**Q3 26**
PFP	n.a	n.a	n.a	38,4%	38,4%	39,4%	40,1%	40,1%	40,5%	40,5%	40,0%	40,3%	41,1%
NPE	n.a	n.a	n.a	-	-	-	-	-	-	-	-	-	-
PFA	6,1%	7,8%	9,7%	11,1%	11,1%	12,7%	15,0%	16,5%	19,3%	19,3%	19,5%	21,8%	23,6%
FT	29,7%	28,6%	27,8%	30,2%	30,2%	28,8%	28,8%	30,9%	28,9%	28,9%	33,0%	33,8%	32,6%
GEA	32,3%	32,3%	32,3%	33,8%	33,8%	34,9%	35,3%	35,4%	36,2%	36,2%	35,7%	36,8%	37,8%

[1] By "organic", GEA means changes that are adjusted for currency and portfolio effects I [2] Before restructuring expenses I [3] Capital Employed as average of the last 4 quarters (L4Q): Since the beginning of the financial year 2021 ROCE has now been considered as „ROCE 3rd Party" (excluding interdivisional effects in the capital employed) at the divisional level.


Engineering
for a better
world.